Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta

Rishi, Pukhraj; Rishi, Ekta; Venkatraman, A.

doi:10.4103/0301-4738.95882

Cited by 11 publications

(24 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Via a similar mechanism, oculopression (ocular massage) can cause dehiscence of Bruch’s membrane as reported by Ruderman et al, 14 or as in our case, widening of the Bruch’s membrane–choroid dehiscence. Rishi et al 15 described a 12-year-old girl with osteogenesis imperfecta, with sudden visual loss in the left eye from choroidal neovascular membrane. She underwent treatment with intravitreal bevacizumab (1.25 mg/0.05 mL).…”

Section: Discussionmentioning

confidence: 99%

Progressive symmetric vertical macular wide angioid streak-like lacquer crack

Mansour¹

2016

IMCRJ

View full text Add to dashboard Cite

PurposeWe report an unusual case of bilateral vertical lacquer crack with no history of ocular trauma and with progressive marked enlargement and consequent visual loss.MethodsThree-year follow-up was completed using best-corrected visual acuity, serial fundus photographs, intravenous fluorescein angiography, and optical coherence tomography.ResultsWe report the occurrence of lacquer crack in a 43-year-old woman with no history of trauma except for laser in situ keratomileusis surgery for mild myopia (as reported by the patient) in the past 5 years and habitual ocular rubbing. Lacquer crack started in the right eye and became evident 1 year later in the left eye. Serial photography after repeated intravitreal injections of ranibizumab for subfoveal choroidal new vessel showed the lacquer crack widened gradually in both eyes. Axial length measurement revealed the presence of high myopia. Best-corrected visual acuity dropped to 20/200 bilaterally.ConclusionWe hypothesize that a thin Bruch’s membrane in high myopia is prone for small rupture initially either spontaneously or following laser in situ keratomileusis and subsequent widening of the rupture by oculopression and intravitreal injections from rise in intraocular pressure.

show abstract

Section: Discussionmentioning

confidence: 99%

Progressive symmetric vertical macular wide angioid streak-like lacquer crack

Mansour¹

2016

IMCRJ

View full text Add to dashboard Cite

show abstract

“…Patients with BCS may therefore benefit from daily monocular monitoring with an Amsler chart, to detect early metamorphopsia (visual distortion), with urgent referral to an ophthalmologist if metamorphopsia develops. CNV has been described in a number of connective tissue disorders including pseudoxanthoma elasticum [ 14 ], Beals-Hecht syndrome [ 15 ], Ehlers-Danlos syndrome [ 16 ], and osteogenesis imperfecta [ 17 ]. Associations between connective tissue disease and CNV have however seldom been investigated at the histological and cellular levels.…”

Section: Discussionmentioning

confidence: 99%

Bruch’s membrane abnormalities in PRDM5-related brittle cornea syndrome

Porter

Gallego-Pinazo

Keeling

et al. 2015

Orphanet J Rare Dis

View full text Add to dashboard Cite

BackgroundBrittle cornea syndrome (BCS) is a rare, generalized connective tissue disorder associated with extreme corneal thinning and a high risk of corneal rupture. Recessive mutations in transcription factors ZNF469 and PRDM5 cause BCS. Both transcription factors are suggested to act on a common pathway regulating extracellular matrix genes, particularly fibrillar collagens. We identified bilateral myopic choroidal neovascularization as the presenting feature of BCS in a 26-year-old-woman carrying a novel PRDM5 mutation (p.Glu134*). We performed immunohistochemistry of anterior and posterior segment ocular tissues, as expression of PRDM5 in the eye has not been described, or the effects of PRDM5-associated disease on the retina, particularly the extracellular matrix composition of Bruch’s membrane.MethodsImmunohistochemistry using antibodies against PRDM5, collagens type I, III, and IV was performed on the eyes of two unaffected controls and two patients (both with Δ9-14 PRDM5). Expression of collagens, integrins, tenascin and fibronectin in skin fibroblasts of a BCS patient with a novel p.Glu134* PRDM5 mutation was assessed using immunofluorescence.ResultsPRDM5 is expressed in the corneal epithelium and retina. We observe reduced expression of major components of Bruch’s membrane in the eyes of two BCS patients with a PRDM5 Δ9-14 mutation. Immunofluorescence performed on skin fibroblasts from a patient with p.Glu134* confirms the generalized nature of extracellular matrix abnormalities in BCS.ConclusionsPDRM5-related disease is known to affect the cornea, skin and joints. Here we demonstrate, to the best of our knowledge for the first time, that PRDM5 localizes not only in the human cornea, but is also widely expressed in the retina. Our findings suggest that ECM abnormalities in PRDM5-associated disease are more widespread than previously reported.Electronic supplementary materialThe online version of this article (doi:10.1186/s13023-015-0360-4) contains supplementary material, which is available to authorized users.

show abstract

“…At 3-month follow-up, there were no complications, and vision and OCT both remained stable. 48 Since then, a number of case reports have been published on the successful use of bevacizumab for CNVM in a number of pediatric diseases including high myopia, 49,50 trauma, 51 osteogenesis imperfecta, 52 idiopathic intracranial hypertension, 53 toxoplasmosis, 54,55 choroidal osteoma, 56 Best disease, 57,58 cat scratch disease, 59 optic nerve and retinochoroidal coloboma, 60 and hamartoma of the retina and retinal pigment epithelium (RPE). 55 In the first large series, Kozak et al 61 reported on a retrospective, multicenter interventional case series of 39 children aged 3-17 years with CNVM due to various etiologies treated with anti-VEGF agents (34 bevacizumab or 5 ranibizumab).…”

Section: Cnvmsmentioning

confidence: 99%

The use of bevacizumab in pediatric retinal and choroidal disease: A review

Belin

Lee

Greaves

et al. 2019

European Journal of Ophthalmology

View full text Add to dashboard Cite

The use of intravitreal bevacizumab in pediatric retinal and uveitic disease has become more widespread over the past decade. This article serves to outline the rationale underlying the use of intravitreal bevacizumab, and which disease entities it should be appropriately thought of as a primary or solo therapy, as opposed to an adjuvant one. Also presented is the relevant literature regarding each of these retinopathies.

show abstract

Intravitreal bevacizumab for treatment of choroidal neovascularization associated with osteogenesis imperfecta

Cited by 11 publications

References 7 publications

Progressive symmetric vertical macular wide angioid streak-like lacquer crack

Progressive symmetric vertical macular wide angioid streak-like lacquer crack

Bruch’s membrane abnormalities in PRDM5-related brittle cornea syndrome

The use of bevacizumab in pediatric retinal and choroidal disease: A review

Contact Info

Product

Resources

About